CipA of Acinetobacter baumannii Is a Novel Plasminogen Binding and Complement Inhibitory Protein

Area of Science:

• Microbiology
• Immunology
• Pathogenesis

Background:

• Acinetobacter baumannii is a significant cause of nosocomial infections, often exhibiting multidrug resistance.
• Increasing resistance poses challenges for treating Gram-negative bacterial infections.
• Understanding immune evasion mechanisms is crucial for combating Acinetobacter baumannii infections.

Purpose of the Study:

• To identify novel factors contributing to Acinetobacter baumannii's serum resistance and pathogenesis.
• To elucidate the role of immune evasion strategies in persistent infections.

Main Methods:

• Identification and characterization of a novel plasminogen-binding protein, CipA.
• In vitro assays to assess CipA's effect on complement pathways and its interaction with plasminogen.
• Generation and testing of a CipA-deficient mutant for serum resistance and endothelial cell invasion.

Main Results:

• A novel plasminogen-binding protein, CipA, was identified in Acinetobacter baumannii.
• Bound plasminogen, activated by CipA, degraded complement C3b and fibrinogen, enhancing serum resistance.
• CipA directly inhibited the alternative complement pathway independently of plasminogen binding.
• A CipA-deficient mutant exhibited increased susceptibility to human serum and impaired endothelial cell penetration.

Conclusions:

• CipA is a multifunctional virulence factor essential for Acinetobacter baumannii pathogenesis.
• CipA contributes to serum resistance through both plasminogen-dependent and -independent mechanisms.
• Targeting CipA may represent a novel therapeutic strategy against Acinetobacter baumannii infections.